【Animal modeling】-β-aminopropionitrile combined with angiotensin Ⅱ modified method to establish mouse model of aortic dissection

  Objective To explore an improved method for constructing aortic dissection model in mice.

  Methods A mouse model of aortic dissection was established with β-aminopropionitrile combined with angiotensin II. 100 6-week-old males

  Twenty C57BL/6J mice were randomly selected as the control group, and the other 80 were used for modeling, including 40 in the pure BAPN group and 40 in the BAPN+Ang-Ⅱ group. Mice in BAPN group were given 0.1 g·kg-1·d-1 BAPN drinking water; mice in BAPN+Ang-Ⅱ group were given BAPN 0.1 g·kg-1·d-1 drinking water, subcutaneously injected with Ang-Ⅱ (according to time). Adjusted injection dose: 1-7 days Ang-Ⅱ dose is 1.5 mg·kg-1·d-1, 8-14 days Ang-Ⅱ is 0.75 mg·kg-1·d-1, 15-16 days Ang-Ⅱ 0.375 mg·kg-1·d-1), the BAPN group was injected with an equal volume of normal saline. Materials were collected after 16 days of drug intervention. The body weight and water intake of the mice were recorded. If the mice died during the experiment, they were immediately dissected to analyze the cause of death. On the 17th day of the experiment, the undead mice were sacrificed by cervical dislocation, and the tissues were collected for use; HE staining was used to judge the formation of aortic dissection.

  Results Compared with the control group, the BAPN+Ang-Ⅱ group and the BAPN group had a decrease in water intake and a slower increase in body weight (P<0.05). The incidence of dissection and mortality were 0 in the control group; the incidence of dissection in the BAPN group was 7.5%, and the mortality was 2.5%; the incidence of dissection in the BAPN+Ang-Ⅱ group was 80%, and the mortality was 30%. All mice in BAPN+Ang-Ⅱ group died 1-3 days after adjusting the dose of Ang-Ⅱ, and 83.3% of the mice died within minutes after the injection of the drug.

  Conclusion The model of aortic dissection was successfully established by giving C57BL/6J mice continuous BANP drinking water combined with subcutaneous injection of Ang-Ⅱ.